Research advances in the role of lymphocyte activation gene-3 in liver-related diseases
DOI:10.3969/j.issn.1001-5256.2021.04.056
- VernacularTitle:淋巴细胞活化基因3在肝脏相关疾病中的研究进展
- Author:
Rui CHEN
1
;
Zhixin WANG
;
Haining FAN
;
Haijiu WANG
Author Information
1. Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Qinghai University, Qinghai Province Key Laboratory of Hydatid Disease Research, Xining 810001, China
- Publication Type:Research Article
- Keywords:
Liver Diseases;
Immunosuppression;
Therapeutics
- From:
Journal of Clinical Hepatology
2021;37(4):977-981
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) therapy has shown broad prospects in the treatment of malignant tumors and infectious diseases, but problems encountered during application drive researchers to explore potential immune checkpoints. This article summarizes the research advances in the role of the new immune checkpoint lymphocyte activation gene-3 (LAG-3) in liver-related diseases, aiming to provide a reference for subsequent research. LAG-3 is expected to become the classic target of next-generation ICIs therapy and play a key role in immunotherapy for liver-related diseases.
